Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects

BACKGROUND: Ethambutol (EMB) is one of the first-line drugs in the treatment against tuberculosis (TB). Side-effects are infrequent, but its main adverse effect, optical neuropathy, has long been recognised. The mechanisms of action and predisposing factors have not yet been fully understood.METHOD:...

Full description

Saved in:
Bibliographic Details
Published inThe international journal of tuberculosis and lung disease Vol. 12; no. 8; pp. 967 - 971
Main Authors HASENBOSCH, R. E, ALFFENAAR, J. W. C, KOOPMANS, S. A, KOSTERINK, J. G. W, VAN DER WERF, T. S, VAN ALTENA, R
Format Journal Article
LanguageEnglish
Published Paris, France IUATLD 01.08.2008
Union internationale contre la tuberculose et les maladies respiratoires
Subjects
Online AccessGet full text
ISSN1027-3719

Cover

More Information
Summary:BACKGROUND: Ethambutol (EMB) is one of the first-line drugs in the treatment against tuberculosis (TB). Side-effects are infrequent, but its main adverse effect, optical neuropathy, has long been recognised. The mechanisms of action and predisposing factors have not yet been fully understood.METHOD: We conducted a retrospective study (1992-2007) in an attempt to find predisposing factors for optical neuropathy.RESULTS: Visual disturbance was reported in 1.3% of the 760 patients treated with EMB; of these, 0.8% were EMB-related. We present the six cases; four were clearly overdosed, but in two obese patients dosage was correctly calculated for total body weight (TBW).CONCLUSION: Analysis of the case histories and previous reports suggest that optical neuropathy may at least partly be caused by EMB overdosing due to daily dosing based on TBW instead of dosing on lean body mass.
Bibliography:(R) Medicine - General
1027-3719(20080801)12:8L.967;1-
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Case Study-2
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ISSN:1027-3719